Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 18, 2020

Moleculin, UTMB partner to study WP1122 for coronavirus

Moleculin Biotech has partnered with the University of Texas Medical Branch at Galveston (UTMB) to test its molecular inhibitors, including WP1122, to treat different viruses, including coronavirus.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Moleculin Biotech has partnered with the University of Texas Medical Branch at Galveston (UTMB) to test its molecular inhibitors, including WP1122, to treat different viruses, including coronavirus.

UTMB’s Center for Biodefense and Emerging Infectious Diseases works with Galveston National Laboratory, the US Department of Defense and the US Centers for Disease Control & Prevention, among other partners.

Under the deal, Moleculin will supply WP1122 and related inhibitors, as well as provide technical support.

UTMB will start assessing these candidates against different viral disease models, including Covid-19, in alliance with UTMB Center for Biodefense and Emerging Infectious Diseases.

Moleculin Biotech chief science officer Dr Donald Picker said: “The in vivo research supporting the use of 2-DG as dual inhibitor of glycolysis and glycosylation to defeat viruses like coronavirus through multiple effects critical to the progression of viral infection is promising.

“And, with the improved drug-like properties of WP1122 and an apparent ability to increase concentration of the drug in the infected organs, we are excited to begin testing against coronavirus, as well as others. Our hope for this kind of therapeutic approach is not only as a potential treatment for infected patients, but even as a possible preventative measure.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU